NRDL 2026 Update Review: What It Means for Foreign Pharma in China

The 2026 revision of China’s National Reimbursement Drug List (国家医保目录, National Reimbursement Drug List, guójiā yībǎo mùlù) added an estimated 45 new drugs while imposing an average price reduction of 52% on negotiated products, marking the eighth consecutive annual update of the country’s primary market-access gateway. For foreign pharmaceutical companies, the 2026 cycle signals both a tightening of pricing expectations and an expansion of coverage scope: 18 of the 45 new additions come from multinational firms, compared with 14 in 2025, indicating that Beijing is willing to include innovative foreign drugs — provided the price is right. This review breaks down the 2026 NRDL changes, the evolving price-volume tradeoff, and what foreign pharma executives must do to stay competitive.

NRDL 2026: Key Changes and Drug Coverage Expansion

The 2026 NRDL update covers a total of 3,289 reimbursable drugs, up from 3,158 in 2025. Among the 45 new additions, 12 are oncology therapies, 9 target rare diseases, and 8 are chronic-disease treatments (cardiovascular, diabetes, respiratory). Foreign firms secured listings in oncology (6 drugs), rare diseases (5), and neurology (3), but faced a median price cut of 55% for their products — slightly deeper than the 48% average for domestic counterparts.

The National Healthcare Security Administration (NHSA) also removed 21 drugs in 2026, including 4 foreign-patent-expired products that failed cost-effectiveness thresholds. This “dynamic adjustment” mechanism, introduced in 2017, now operates on a predictable annual cycle: applications open in May, expert review in August, price negotiation in November, and implementation from January 1 the following year.

A notable structural shift in 2026 is the inclusion of 7 cell and gene therapies (CAR-T, gene-editing drugs), 3 of which are from foreign firms. While these therapies come with high list prices (¥1.2 million–¥3 million per treatment), the NHSA negotiated confidential rebate structures rather than fixed price reductions, signaling a new willingness to accommodate novel modalities — but only for products with strong real-world evidence (RWE) from Chinese patients.

The Price Negotiation Reality: Volume-for-Price Commitment

The core mechanism of NRDL inclusion remains the volume-for-price tradeoff: a drug that passes price negotiation gains guaranteed reimbursement access across China’s 1.4 billion population, but at a substantially reduced price. In 2026, the average list-price reduction after negotiation was 52%, with foreign drugs seeing a median cut of 55%. To contextualize, the average reduction in 2020 was 61%, in 2023 it was 57%, and in 2025 it was 50% — meaning 2026 has reversed a two-year trend of gradually shallower cuts. The premium for innovation (the gap between foreign and domestic drug price cuts) widened from 5 percentage points in 2025 to 7 points in 2026.

Despite the deeper cuts, volume commitments have grown. Table 1 shows how NRDL negotiation volumes have scaled over the past four years.

Foreign pharma must view these numbers as both a threat and an opportunity. The 55% average cut means a drug with a global price of $100,000 per patient will generate approximately $45,000 per patient in China — but if the volume commitment holds, a product that would sell 5,000 units globally could sell 15,000–20,000 units in China alone. The challenge lies in forecasting whether hospital-level listing (进院, jìn yuàn, entry into hospital) actually materializes after NRDL approval.

Foreign Pharma Performance: Winners and Losers

Among foreign firms in the 2026 NRDL cycle, Roche secured four new listings (two oncology antibodies, one rare-disease enzyme replacement, one neurology biologic), while Novartis gained three (two CAR-T programs and one respiratory biologic). AstraZeneca, historically the strongest foreign performer in China negotiations, added two diabetes drugs but failed to negotiate its newest lung cancer compound due to a requested price cut exceeding 70% — a threshold the company deemed unacceptable.

The “AstraZeneca case” encapsulates the 2026 dynamic: the NHSA set a hard ceiling of ¥120,000 per year for oncology drugs in certain therapeutic classes, regardless of origin. Foreign drugs with annual costs above that level — even if superior in efficacy — faced either exclusion or a 70%+ reduction. This is a departure from earlier cycles where innovation premiums were recognized by the NHSA.

Conversely, smaller foreign biotechs with niche rare-disease portfolios found success. A US-based gene-therapy firm secured NRDL inclusion for its hemophilia B treatment at a confidential price, but with the NHSA agreeing to a three-year volume guarantee and biannual price re-evaluation — a first for gene therapies. This suggests that foreign companies with truly differentiated, hard-to-replicate products can still negotiate favorable terms if they bring robust RWE from Chinese clinical trials.

Strategies for Survival: What Foreign Pharma Must Do Now

Based on the 2026 NRDL outcomes, foreign pharma must recalibrate their China market-entry strategies in three ways.

First, invest in Chinese RWE earlier. The NHSA now demands at least two years of real-world data from Chinese hospitals before considering a negotiation application. In 2026, 14 of the 18 foreign drugs added had completed at least 18 months of Chinese post-marketing studies. Without this data, even the most innovative drug faces an average price cut 8 percentage points deeper than one with RWE.

Second, build a price tolerance model at the global portfolio level. For each drug destined for China, determine the minimum acceptable price (MAP) considering global reference pricing, tiered regulatory demands, and manufacturing costs. Companies that went into 2026 negotiations without a MAP ended up walking away — losing both the negotiation fee (approximately ¥500,000) and a full year of market access. The NHSA does not allow re-application for one year after a failed negotiation.

Third, plan for hospital listing as a separate workstream. NRDL listing does not automatically guarantee hospital formulary inclusion. In 2026, an estimated 35% of newly added foreign drugs still had not achieved hospital listing (进院, jìn yuàn) in more than half of target hospitals six months post-NRDL. Companies need dedicated hospital access teams, often working with local distributors (经销商, jīngxiāo shāng) to navigate the “two-track” system of provincial procurement and hospital evaluation committees.

Looking Ahead: NRDL 2026 and Beyond

The 2026 NRDL update reinforces three structural trends for foreign pharma in China. First, the annual cycle is now predictable and non-negotiable — companies that miss the May application window lose one year. Second, price reductions are stabilizing around 50%–55% for foreign drugs, with no sign of reversal, meaning global pricing strategies must bake in a 50% China discount from day one. Third, the NHSA is increasingly favoring products with Chinese clinical data and local manufacturing, pressuring foreign firms to deepen their China operations beyond commercial-only models.

The implications for 2027 are clear: foreign pharma should expect even tighter scrutiny on cost-effectiveness. The NHSA is piloting a health technology assessment (HTA) framework modeled on NICE (UK), which could impose a ¥150,000 per QALY (quality-adjusted life year) threshold for new drugs. For a foreign oncology drug with a global price of $150,000 per QALY, this would imply a required reduction of 85% — potentially pushing more drugs out of the NRDL entirely. Companies should begin building bilateral HTA collaborations with Chinese academic centers now to shape how value is measured.

Finally, foreign pharma should watch for the expansion of NRDL into outpatient and primary-care settings. In 2026, for the first time, 12 chronic-disease drugs were designated for reimbursement at community health centers (社区卫生服务中心, shèqū wèishēng fúwù zhōngxīn), a lower-cost channel that could erode hospital-based margins but massively expand patient access. Firms with strong primary-care portfolios should prioritize this channel.

NEXT STEPS

1. Assess your NRDL readiness gap. Review our NRDL Application Checklist for Foreign Pharma to identify missing RWE, pricing documentation, or hospital access plans.
2. Build a China price-tolerance model. Use our China Pharma Pricing Calculator to simulate the impact of NRDL price cuts on your global portfolio.
3. Plan your hospital listing strategy. Download the Hospital Access Playbook for Foreign Drugs for step-by-step guidance on post-NRDL formulary entry.

— China Gateway 360 —
Remote China market entry support, built around execution.